ArticleAdvances in therapy2022

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.

Qing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.